Seladelpar

Seladelpar (MBX-8025) is an orally active, potent and specific PPARδ agonist with an EC50 of 2 nM. Seladelpar shows more than 750-fold and 2500-fold selectivity over the PPARα and PPARγ receptors, respectively. Seladelpar can be used for the study of primary biliary cholangitis[1].

Product Specifications

CAS Number

[851528-79-5]

Product Name Alternative

MBX-8025; RWJ-800025

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

PPAR

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

Applications

Neuroscience-Neuromodulation

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/MBX-8025.html

Purity

99.75

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(O)COC1=CC=C(SC[C@H](OCC)COC2=CC=C(C(F)(F)F)C=C2)C=C1C

Molecular Formula

C21H23F3O5S

Molecular Weight

444.46

Precautions

H302, H315, H319, H335

References & Citations

[1]Bays HE, et al. MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin. J Clin Endocrinol Metab. 2011 Sep;96 (9) :2889-97.|[2]Haczeyni F, et al. The selective peroxisome proliferator-activated receptor-delta agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice. Hepatol Commun. 2017 Jul 31;1 (7) :663-674.